SCHEMBL935059

SCHEMBL935059

Cc1cccc(CNC(=O)O)c1C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.54
ALDH1A1 P00352 3/20 0.54
P2RX7 Q99572 2/20 0.54
KDM4C Q9H3R0 1/20 0.51
HTT P42858 1/20 0.50
GAA P10253 1/20 0.50
KMT2A Q03164 1/20 0.50
CDK1 P06493 1/20 0.46
PIM1 P11309 1/20 0.46
MAPKAPK2 P49137 1/20 0.46
GSK3A P49840 1/20 0.46
PLK1 P53350 1/20 0.46
AURKB Q96GD4 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
TSHR P16473 1/20 0.46
CYP2C19 P33261 1/20 0.46
TP53 P04637 1/20 0.46
LMNA P02545 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5670334 0.87 P2RX7 (0.52) HPGDALDH1A1P2RX7KDM4CHTT
SCHEMBL27847330 0.85 P2RX7 (0.51) HPGDALDH1A1P2RX7KDM4CHTT
SCHEMBL2017132 0.84 ALDH1A1 (0.73) HPGDALDH1A1HTTGAAKMT2A
SCHEMBL3921086 0.84 P2RX7 (0.57) HPGDALDH1A1P2RX7KDM4CHTT
SCHEMBL7034976 0.82 HPGD (0.43) HPGDALDH1A1P2RX7KDM4CHTT
SCHEMBL5929981 0.81 HPGD (0.50) HPGDALDH1A1P2RX7HTTGAA
SCHEMBL17646067 0.81 RIPK1 (0.46) HPGDALDH1A1P2RX7HTTGAA
SCHEMBL3131049 0.81 P2RX7 (0.56) HPGDALDH1A1P2RX7GAAKMT2A
SCHEMBL3126847 0.81 P2RX7 (0.56) HPGDP2RX7LMNA
SCHEMBL8765952 0.81 GAA (0.51) HPGDALDH1A1P2RX7KDM4CHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090023667-A1 Composition For Preventing Harmful Organisms MITSUI CHEMICALS, INC. (JP) 2009-01-22 US claimed
EP-2003968-A2 COMPOSITIONS AND METHODS TO ADD VALUE TO PLANT PRODUCTS, SO INCREASING THE COMMERCIAL QUALITY, RESISTANCE TO EXTERNAL FACTORS AND POLYPHENOL CONTENT THEREOF Leschot Sanhueza, Andres Antonio (CL) 2008-12-24 EP claimed
EP-1872658-A1 PESTICIDAL COMPOSITION Mitsui Chemicals, Inc. (JP) 2008-01-02 EP claimed
US-20070232495-A1 Compositions and methods to add value to plant products, increasing the commercial quality, resistance to external factors and polyphenol content thereof NAPPA ALVARO O 2007-10-04 US claimed
WO-2007110801-A2 COMPOSITIONS AND METHODS TO ADD VALUE TO PLANT PORDUCTS, INCREASING THE COMMERCIAL QUALITY, RESISTANCE TO EXTERNAL FACTORS AND POLYPHENOL CONTENT THEREOF LESCHOT SANHUEZA ANDRES ANTONI (CL) 2007-10-04 WO claimed
US-20050171064-A1 Insecticide for Acarina comprising synergistic mixture including a 4-nitroimino or 4-cyanoimino 1,3,5-oxadiazine such as 5-(2-chlorothiazol-5-ylmethyl)-3-methyl-4-nitroimino-perhydro-1,3,5-oxadiazine and another pesticide such as pirimicarb SENN ROBERT (CH) 2005-08-04 US claimed
CN-110325040-B Plant disease control composition and method for controlling plant disease using same 三井化学AGRO株式会社 2022-04-05 CN disclosed
EP-3710453-A1 SINGLE ENANTIOMER ANTIPARASITIC COMPOUNDS Avista Pharma Solutions, Inc. (US) 2020-09-23 EP disclosed
CN-110325040-A Plant disease control composition and apply its plant disease the method for control 三井化学AGRO株式会社 2019-10-11 CN disclosed
WO-2018009751-A1 ANTIPARASITIC COMPOUNDS AVISTA PHARMA SOLUTIONS, INC. (US) 2018-01-11 WO disclosed
WO-2017201134-A1 SYNTHETIC PROCESS AND NOVEL INTERMEDIATES AVISTA PHARMA SOLUTIONS, INC. (US) 2017-11-23 WO disclosed
EP-3245209-A1 ANTIPARASITIC COMPOUNDS Avista Pharma Solutions, Inc. (US) 2017-11-22 EP disclosed
WO-2016183173-A1 ANTIPARASITIC COMPOUNDS Avista Pharma Solutions (US) 2016-11-17 WO disclosed
CN-101160052-A Pesticidal composition MITSUI CHEMICALS INC (JP) 2008-04-09 CN disclosed
EP-1872658-A1 PESTICIDAL COMPOSITION Mitsui Chemicals, Inc. (JP) 2008-01-02 EP disclosed
US-20070232495-A1 Compositions and methods to add value to plant products, increasing the commercial quality, resistance to external factors and polyphenol content thereof NAPPA ALVARO O 2007-10-04 US disclosed
WO-2007110801-A2 COMPOSITIONS AND METHODS TO ADD VALUE TO PLANT PORDUCTS, INCREASING THE COMMERCIAL QUALITY, RESISTANCE TO EXTERNAL FACTORS AND POLYPHENOL CONTENT THEREOF LESCHOT SANHUEZA ANDRES ANTONI (CL) 2007-10-04 WO disclosed
EP-1165527-A1 PESTICIDAL ENANTIOMER-PURE 2,4-DISUBSTITUTED OXAZOLINES Novartis AG (CH) 2002-01-02 EP disclosed
WO-2000058291-A1 PESTICIDAL ENANTIOMER-PURE 2,4-DISUBSTITUTED OXAZOLINES NOVARTIS AG (CH) 2000-10-05 WO disclosed
EP-0255760-A1 A process for the production of a granule-shaped composition comprising agricultural chemical compound MEIJI SEIKA KAISHA LTD. (JP) 1988-02-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171064-A1 Insecticide for Acarina comprising synergistic mixture including a 4-nitroimino or 4-cyanoimino 1,3,5-oxadiazine such as 5-(2-chlorothiazol-5-ylmethyl)-3-methyl-4-nitroimino-perhydro-1,3,5-oxadiazine and another pesticide such as pirimicarb CNPY2, CBR3, CNPY3 HPGD 1823/4885ALDH1A1 2115/4885P2RX7 174/4885
US-20070232495-A1 Compositions and methods to add value to plant products, increasing the commercial quality, resistance to external factors and polyphenol content thereof C5, PNN, NQO1 HPGD 955/4885ALDH1A1 3137/4885P2RX7 2948/4885
US-20090023667-A1 Composition For Preventing Harmful Organisms DDT, CBR3, AHR HPGD 3824/4885ALDH1A1 439/4885P2RX7 2395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.